Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Equity (2016 - 2025)

Historic Return on Equity for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 5.2%.

  • Coherus Oncology's Return on Equity rose 71800.0% to 5.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.2%, marking a year-over-year increase of 71800.0%. This contributed to the annual value of 0.18% for FY2024, which is 16100.0% down from last year.
  • As of Q3 2025, Coherus Oncology's Return on Equity stood at 5.2%, which was up 71800.0% from 17.85% recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Return on Equity peaked at 45.8% during Q2 2022, and registered a low of 17.85% during Q2 2025.
  • Over the past 5 years, Coherus Oncology's median Return on Equity value was 0.37% (recorded in 2021), while the average stood at 1.46%.
  • In the last 5 years, Coherus Oncology's Return on Equity surged by 469600bps in 2022 and then crashed by -443700bps in 2023.
  • Over the past 5 years, Coherus Oncology's Return on Equity (Quarter) stood at 2.51% in 2021, then skyrocketed by 199bps to 2.49% in 2022, then crashed by -42bps to 1.45% in 2023, then tumbled by -380bps to 4.07% in 2024, then skyrocketed by 228bps to 5.2% in 2025.
  • Its Return on Equity was 5.2% in Q3 2025, compared to 17.85% in Q2 2025 and 1.7% in Q1 2025.